News
Myasthenia gravis (MG) in children and adolescents to age 18 -- juvenile MG -- includes clinically significant developmental ...
MyChesCo on MSN12h
Johnson & Johnson Highlights Promising Data on IMAAVY™ for Generalized Myasthenia GravisHOUSE, PA — Johnson & Johnson (NYSE: JNJ) has unveiled new data demonstrating the efficacy of IMAAVY™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG). Presented at the ...
In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant ...
Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback